Kevin is an experienced drug developer and recognized leader in cell and gene therapy. Prior to Kelonia, Kevin built and managed the oncology gene therapy pipeline at Bluebird Bio as VP of Oncology Research and Development where he was responsible for developing several medicines including the first approved anti-BCMA CAR T cell for treatment of Multiple Myeloma (Abecma). Kevin speaks at numerous industry and investor events, most recently at BioCentuiry's Grand Rounds conference in 2024. Kevin received his PhD from Oregon Health and Sciences University and was trained in the Surgery branch at the National Cancer Institute. Kevin's name appears on numerous patents and publications from throughout his over twenty years of experience working in cell and gene therapies.